Obinutuzumab: The more the merrier?

Keyphrases

• Obinutuzumab 100%
• No Significant Difference 50%
• High Dose 50%
• Progression-free Survival 50%
• Previously Untreated Patients 50%
• Phase II Study 50%
• Overall Response Rate 50%
• Chronic Lymphocytic Leukemia 50%
• Randomized Phase II Trial 50%
• Between-group 50%
• Anti-CD20 Antibody 50%

Medicine and Dentistry

• Obinutuzumab 100%
• Rituximab 50%
• Progression Free Survival 50%
• Drug Megadose 50%
• B-Cell Chronic Lymphocytic Leukemia 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Obinutuzumab 100%
• Progression Free Survival 50%
• Chronic Lymphatic Leukemia 50%
• Rituximab 50%